Sponsors & Exhibitors Profile
Histogenetics, based in New York, USA, is an international leader in DNA sequence-based tissue typing (SBT) services and serves clients around the globe. Histogenetics mastered Next Generation Sequencing (NGS) and Third generation sequencing technologies (PacBio) for routine HLA typing for ultimate resolution and quality at high volume.
Identification of high resolution tissue type is crucial in determining a suitable match in tissue and organ transplant. The better the match the more successful is the transplant. Histogenetics has been working with the world’s largest donor centers, National Marrow Donor Program (NMDP), German Donor Center (DKMS), Office of Naval research (ONR)and many other international registries. It is Histogenetics’ goal to help patients by applying its cutting edge technology to speed up the transplant process and saving lives otherwise lost if the process were slower.
We are entering the era of personalized medicine and knowing each individual’s genetic makeup will determine how the treatment should be tailored for each person. Histogenetics is currently studying other genes that might elucidate the complex genetic basis of health and disease.
One Lambda, Inc., is a leader in transplant diagnostics and continues to offer a broad range of products to support clinicians and laboratories in the management of transplant patients.
Our portfolio of HLA typing technologies provides a complete array of technologies to address the workflows of any laboratory. These include serology, SSP, R‐SSO‐LABScan 3D, and Sequence Based Typing (SBT). With the introduction of NXType™, we now have a complete Next Generation Sequencing typing solution from sample preparation to data analysis, using TypeStream™. We look forward to the introduction of real time PCR to complete the entire spectrum of typing solutions available to the global HLA community.
In addition to donor specific antibody (DSA) assays, our line of antibody monitoring products includes both complement and non‐complement binding assays. Our research use only biomarkers, AT1R and ETAR are available as ELISA assays. With LABScreen® Multi, we are the only company to offer a CE marked, IVD approved assay for the detection of HLA Class I, HLA Class II and Human Neutraphil Antibodies (HNA) 1 ‐5.
Visit the One Lambda website www.onelambda.com to discover how we can help you improve the standard of care in your transplant programs.
Laboratory Corporation of America® Holdings, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people’s health by delivering the combination of world-class diagnostics, drug development and knowledge services. LabCorp provides leading-edge medical laboratory services through a sophisticated network of primary clinical and specialty testing laboratories. LabCorp consist of 48,000 employees worldwide, providing scientific expertise in esoteric testing, genomics and clinical and anatomic pathology. LabCorp’s Identity Testing Division offers comprehensive HLA Next Generation Sequencing (NGS) technology, HLA Antibody Analysis, Pre/Post Engraftment Monitoring, and Bio-sample Processing services in support of international donor registries, transplant centers, research and pharmaceutical companies.
Takeda Pharmaceuticals (Asia Pacific) Pte Ltd, located in Singapore, is the marketing and sales organization of Takeda Pharmaceutical Company Limited.
As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda’s mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Areas of focus include cardiovascular and metabolic diseases, immunology and respiratory diseases, oncology and central nervous system diseases, among others. Through the integration of Millennium Pharmaceuticals and Nycomed, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach. Additional information is available through its website, www.takeda.com.
At Pfizer Singapore, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, and many of the world’s best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care in Singapore.